Japan Tissue Engineering Co., Ltd.
Tokyo Stock Exchange 7774.T
Japan Tissue Engineering Co., Ltd. Gross Profit Margin for the year ending March 31, 2024: 67.24%
-
Japan Tissue Engineering Co., Ltd. Gross Profit Margin for the year ending March 31, 2023 was 55.92%, a -6.31% change year over year.
-
Japan Tissue Engineering Co., Ltd. Gross Profit Margin for the year ending March 31, 2022 was 59.69%, a 16.47% change year over year.
-
Japan Tissue Engineering Co., Ltd. Gross Profit Margin for the year ending March 31, 2021 was 51.25%, a -0.37% change year over year.
-
Japan Tissue Engineering Co., Ltd. Gross Profit Margin for the year ending March 31, 2020 was 51.44%, a -5.59% change year over year.
| Date | Gross Profit Margin | Operating Income Margin | EBT Margin | Net Income Margin |
|---|
| CEO | Mr. Ken-Ichiro Hata D.D.S., Ph.D. |
| IPO Date | Dec. 28, 2007 |
| Location | Japan |
| Headquarters | 6-209-1 Miyakitadori |
| Employees | 211 |
| Sector | Health Care |
| Industries | |
Japan Tissue Engineering Co., Ltd. engages in the regenerative medicine business in Japan. The company operates through Regenerative Medicine Product, Regenerative Medicine Outsourcing, and Research and Development Support segments. It offers autologous cultured epidermis, cartilage, corneal epithelium, and oral mucosal epithelium to medical institutions for the purpose of medical treatment. The company also provides tissue-engineered medical products. In addition, it researches and develops human 3-dimensional cultured tissue models for use in the development of cosmetics and drugs for external use, as well as in research that employs skin and cornea tissues. Further, the company offers regenerative medicine contract development and manufacturing services. The company was founded in 1999 and is headquartered in Gamagori, Japan. Japan Tissue Engineering Co., Ltd. is a subsidiary of Teijin Limited.
Past 5 years
StockViz Staff
January 15, 2025
Any question? Send us an email